In novel cohort, new data confirms decisiondx®-scc provides significant, independent and clinically actionable risk-stratification of patients, including in various high-risk subgroups

Friendswood, texas--(business wire)---- $cstl #cstl--castle biosciences announced a new study in dermatology and therapy that analyzed the independent performance of its decisiondx®-scc test.

CSTL Ratings Summary

CSTL Quant Ranking